ALG3 can increase the radioresistance and tumor stemness of breast cancer cells and can upregulate several key CSC-like markers (Nanog, OCT4, and SOX2) by promoting the glycosylation of TGF-beta receptor II (Sun et al., 2021). Here, SOX2 is linked to breast carcinoma.